Aficamten is a small-molecule cardiac myosin inhibitor used for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve symptoms and functional capacity. It is marketed under the brand name Myqorzo and received U.S. FDA approval in 2025.
Cytokinetics launches MYQORZO for obstructive hypertrophic cardiomyopathy following FDA approval, while C4 Therapeutics doses first patient in Phase 2 trial of cemsidomide for relapsed/refractory multiple myeloma.
The European Commission approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults, completing global regulatory approvals following FDA and China NMPA clearances. First European launch planned in Germany in Q2 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07600177 |
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy |
RECRUITING | PHASE4 |
| NCT06412666 |
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). |
RECRUITING | PHASE2/PHASE3 |
| NCT06116968 |
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM |
COMPLETED | PHASE3 |
| NCT06081894 |
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05924815 |
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval |
COMPLETED | PHASE1 |
